{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasted+State&page=16",
    "query": {
      "intervention": "Fasted State",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 2287,
    "total_pages": 229,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasted+State&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasted+State&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T02:30:18.807Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07714018",
      "title": "Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Cell Carcinoma (RCC)"
      ],
      "interventions": [
        {
          "name": "Intermittent Fasting",
          "type": "OTHER"
        },
        {
          "name": "Continuous Energy Restriction (CER)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-11-01",
      "completion_date": "2028-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07714018"
    },
    {
      "nct_id": "NCT06797674",
      "title": "A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MK-7602",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 34,
      "start_date": "2025-02-10",
      "completion_date": "2025-08-12",
      "has_results": false,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06797674"
    },
    {
      "nct_id": "NCT04505410",
      "title": "Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "A plant based high fiber diet that mimics fasting (\"FMD\") plus advanced therapy",
          "type": "OTHER"
        },
        {
          "name": "Advanced therapy only without dietary intervention",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2020-09-18",
      "completion_date": "2023-12-07",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505410"
    },
    {
      "nct_id": "NCT04672460",
      "title": "A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Solid Tumors",
        "Ovarian Cancer",
        "Breast Cancer",
        "Prostate Cancer",
        "NSCLC",
        "Pancreatic Cancer",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "TALZENNA capsule",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib soft gel capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 73,
      "start_date": "2020-12-21",
      "completion_date": "2022-07-22",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 23,
      "location_summary": "Encinitas, California • Los Angeles, California • San Marcos, California + 12 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04672460"
    },
    {
      "nct_id": "NCT00383162",
      "title": "A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "Combination Product (sumatriptan succinate / naproxen sodium)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 173,
      "start_date": "2006-11",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2017-02-02",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 26,
      "location_summary": "Fresno, California • Newport Beach, California • Santa Monica, California + 23 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00383162"
    },
    {
      "nct_id": "NCT01072604",
      "title": "Pharmacokinetic Study Comparing Aspirin and Aspirin Granules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Acetylsalicylic acid (Aspirin, BAY1019036)",
          "type": "DRUG"
        },
        {
          "name": "Acetylsalicylic acid (Aspirin, BAYE4465)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2009-07",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072604"
    },
    {
      "nct_id": "NCT01954238",
      "title": "A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "GCC-4401C",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Green Cross Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 46,
      "start_date": "2013-08",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 1,
      "location_summary": "Early Phase Clinical Unit _Los Angeles, California",
      "locations": [
        {
          "city": "Early Phase Clinical Unit _Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01954238"
    },
    {
      "nct_id": "NCT05277558",
      "title": "Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type2 Diabetes",
        "Type 2 Diabetes Mellitus in Obese",
        "Dysglycemia",
        "Microvascular Complications",
        "Brain Structure",
        "Obesity, Childhood",
        "Diabetes in Adolescence",
        "Inflammation",
        "Insulin Resistance",
        "Overweight, Childhood",
        "Cognitive Decline"
      ],
      "interventions": [
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 117,
      "start_date": "2022-05-24",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05277558"
    },
    {
      "nct_id": "NCT00865748",
      "title": "A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Metformin HCl 500 mg tablets, single dose",
          "type": "DRUG"
        },
        {
          "name": "CLUCOPHAGE® XR 500 mg tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2004-01",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865748"
    },
    {
      "nct_id": "NCT05317390",
      "title": "Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dystonia",
        "Drug Induced Dystonia",
        "Parkinson Disease",
        "Essential Tremor",
        "Dyskinesias",
        "Myoclonus",
        "Tic Disorders",
        "Torticollis",
        "Ulnar Nerve Entrapment",
        "Temporomandibular Joint Disorders",
        "Dysphonia"
      ],
      "interventions": [
        {
          "name": "DystoniaNet-based diagnosis of isolated dystonia",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2022-06-01",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-11-12T02:30:18.807Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317390"
    }
  ]
}